PhotoPharmics Phase 2 Parkinson’s Disease
April 16, 2026
PhotoPharmics will be attending the American Academy of Neurology Annual Meeting (AAN) in Chicago, April 18-22. PhotoPharmics’ pivotal Phase 3 Light for Parkinson’s Disease clinical trial is in its final weeks, and topline results will likely be shared at the World Parkinson Congress in late May. This fully remote, randomized, double-blind, placebo-controlled study is evaluating Celeste®, an investigational photo-neuromodulation device, in individuals living with Parkinson’s disease.
If you’ll be at AAN, drop by the PhotoPharmics Booth, #3614.
Recent News
- Freyya Closes Oversubscribed Pre-Seed Financing to Advance FDA Regulatory Milestones, Commercialization
- In Memory of Dr. Michael Rinck, Founder, MT Promedt Consulting GmbH
- bioMérieux Launches SPINCHIP® hs-cTnl, a Major Innovation for the Measurement of High-Sensitivity Cardiac Troponin I and Faster Management of Cardiac Emergencies
- Priority Review Granted for PolarityBio’s SkinTE for Treatment of Diabetic Foot Ulcers
- National Institutes of Health Award Inherent Biosciences a Direct-to-Phase II SBIR Grant
- Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
